Zepbound KwikPen contains tirzepatide, an innovative dual GIP and GLP-1 receptor agonist designed to help adults manage obesity and excess weight. The medication is administered as a once-weekly subcutaneous injection using a convenient multi-dose KwikPen device that contains four weekly doses. The pen is intended for single-patient use and is available in six dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

Zepbound works by targeting the body's natural appetite-regulating hormones. By activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, it helps reduce hunger, increase feelings of fullness, and decrease food consumption, supporting sustainable weight loss and long-term weight management.

The medication is indicated for adults with obesity, or adults who are overweight and have at least one weight-related medical condition. It is also approved for certain adults with obesity and moderate-to-severe obstructive sleep apnea (OSA). Treatment should always be used alongside a reduced-calorie diet and increased physical activity.

Clinical studies have demonstrated substantial weight-loss benefits with tirzepatide treatment, making Zepbound one of the leading prescription weight-management therapies available. Results vary between individuals, and treatment should be undertaken under the supervision of a qualified healthcare professional.

Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Patients should review the full prescribing information and discuss potential risks and benefits with their healthcare provider before starting treatment.